
  
    
      
        Background_NNP
        Glycosaminoglycans_NNP (_( GAGs_NNP )_) are_VBP negatively_RB charged_VBN
        polysaccharides_NNS derived_VBN from_IN an_DT amino_JJ hexose_NN ._. They_PRP are_VBP
        structural_JJ and_CC functional_JJ modulators_NNS of_IN extracellular_NN
        matrices_NNS that_WDT play_VBP important_JJ roles_NNS in_IN CNS_NNP development_NN and_CC
        repair_NN ._. They_PRP exhibit_NN both_DT stimulatory_NN and_CC inhibitory_NN
        influences_VBZ on_IN neurite_NN outgrowth_NN and_CC survival_NN ._. Evidence_NN
        demonstrates_VBZ the_DT ability_NN of_IN heparin_NN sulfates_NNS (_( HSs_NNP )_) to_TO bind_NN
        to_TO growth_VB /_NN trophic_JJ factors_NNS and_CC selectively_RB regulate_VB such_JJ
        factors_NNS '_POS receptors_NNS ._. [_NN 1_CD 2_CD ]_NN ._. They_PRP can_MD act_VB as_IN co-receptors_JJ
        of_IN growth_NN /_NN trophic_JJ and_CC survival_NN factors_NNS to_TO regulate_VB cell_NN
        behavior_NN and_CC /_NN or_CC restrict_VB diffusion_NN and_CC create_VB a_DT relatively_RB
        high_JJ local_JJ concentration_NN of_IN ligand_NN ._.
        Pigment_NNP epithelium-derived_JJ factor_NN (_( PEDF_NNP )_) is_VBZ an_DT
        extracellular_NN neuronal_NN differentiation_NN and_CC survival_NN factor_NN
        for_IN cells_NNS derived_VBN from_IN the_DT retina_NN and_CC CNS_NNP ._. It_PRP induces_VBZ
        neuronal_NN differentiation_NN in_IN retinoblastoma_NN cells_NNS ,_, protects_VBZ
        retina_NN neurons_NNS (_( including_VBG photoreceptors_NNS )_) from_IN death_NN by_IN
        apoptosis_NNS and_CC other_JJ insults_NNS ,_, and_CC has_VBZ a_DT morphogenetic_JJ effect_NN
        on_IN photoreceptor_NN cells_NNS [_NN 3_CD 4_CD 5_CD 6_CD ]_NN ._. It_PRP also_RB has_VBZ
        neurotrophic_JJ effects_NNS on_IN neurons_NNS from_IN the_DT cerebellum_NN ,_,
        hippocampus_JJ and_CC spinal_JJ cord_NN [_NN 7_CD 8_CD 9_CD 10_CD 11_CD 12_CD ]_NN ._. In_IN the_DT
        intact_JJ retina_NN ,_, this_DT factor_NN is_VBZ identified_VBN as_IN a_DT secreted_JJ
        protein_NN associated_VBN by_IN ionic_JJ interactions_NNS with_IN the_DT
        interphotoreceptor_NN matrix_NN [_NN 13_CD 14_CD ]_NN ,_, where_WRB GAGs_NNP are_VBP the_DT
        major_JJ polyanionic_JJ components_NNS ._.
        Biochemically_NNP ,_, PEDF_NNP is_VBZ a_DT 50_CD -_: kDa_NN glycoprotein_NN with_IN
        structural_JJ homology_NN to_TO members_NNS of_IN the_DT serine-protease_JJ
        inhibitor_NN (_( serpin_NN )_) superfamily_RB [_NN 3_CD 15_CD ]_NN ._. However_RB ,_, it_PRP has_VBZ
        no_DT inhibitory_NN effects_NNS on_IN proteases_NNS ._. Its_PRP$ neurotrophic_JJ
        activities_NNS are_VBP independent_JJ of_IN its_PRP$ protease_NN inhibition_NN
        potential_JJ but_CC dependent_JJ on_IN its_PRP$ interaction_NN with_IN
        cell-surface_JJ receptors_NNS [_NN 9_CD 12_CD 16_CD 17_CD 18_CD ]_NN ._. PEDF_NNP has_VBZ high_JJ
        binding_JJ affinity_NN for_IN cell-surface_JJ receptors_NNS in_IN human_JJ
        retinoblastoma_NN Y-_NNP 79_CD cells_NNS (_( K_NNP 
        
          d_SYM 
         =_SYM 2_CD ._. 7_CD nM_NN )_) ,_, which_WDT is_VBZ mediated_JJ by_IN interactions_NNS between_IN a_DT
        region_NN spanning_VBG amino_JJ acid_NN positions_NNS 78_CD -_: 121_CD of_IN the_DT PEDF_NNP
        polypeptide_NN and_CC the_DT extracellular_NN domains_NNS of_IN the_DT receptor_NN
        protein_NN [_NN 18_CD ]_NN ._. Blockage_NNP of_IN these_DT interactions_NNS inhibits_NNS
        the_DT PEDF_NNP neurotrophic_JJ effects_NNS ._. PEDF_NNP also_RB has_VBZ binding_JJ
        affinity_NN for_IN GAGs_NNP ,_, such_JJ as_IN ,_, heparin_NN ,_, heparin-_NN and_CC
        chondroitin-sulfates_JJ ,_, but_CC this_DT affinity_NN is_VBZ ~_NN 1000_CD -_: fold_VB lower_JJR
        than_IN for_IN the_DT receptor_NN (_( e_SYM ._. g_SYM ._. ,_, K_NNP 
        
          d_SYM 
         4_CD μM_NN for_IN the_DT heparin-_NN PEDF_NNP interactions_NNS )_) [_NN 14_CD 19_CD ]_NN ._.
        The_DT binding_JJ to_TO GAGs_NNP is_VBZ mediated_JJ by_IN ionic_JJ interactions_NNS
        between_IN an_DT area_NN clustered_VBN with_IN positively_RB charged_VBN lysines_NNS
        of_IN PEDF_NNP and_CC the_DT negatively_RB charged_VBN GAGs_NNP ._. In_IN the_DT PEDF_NNP
        spatial_NN structure_NN ,_, the_DT putative_JJ GAG_NNP binding_JJ domain_NN is_VBZ
        distinct_JJ from_IN and_CC non-overlapping_JJ with_IN the_DT neurotrophic_JJ
        active_JJ region_NN [_NN 14_CD 20_CD ]_NN ._.
        Because_IN PEDF_NNP coexists_NNS with_IN GAGs_NNP in_IN extracellular_NN
        matrices_NNS and_CC has_VBZ binding_JJ affinity_NN for_IN them_PRP ,_, it_PRP is_VBZ of_IN
        interest_NN to_TO investigate_VB the_DT role_NN of_IN GAGs_NNP on_IN PEDF_NNP activity_NN ._.
        Given_VBN that_IN binding_JJ to_TO cell-surface_JJ receptors_NNS is_VBZ the_DT first_JJ
        step_NN in_IN the_DT biological_JJ activity_NN of_IN PEDF_NNP ,_, we_PRP used_VBD human_JJ
        retinoblastoma_NN Y-_NNP 79_CD cells_NNS and_CC their_PRP$ conditioned_VBN media_NNS (_( CM_NNP )_)
        as_IN sources_NNS of_IN functional_JJ PEDF_NNP receptors_NNS and_CC extracellular_NN
        matrix_NN components_NNS ,_, respectively_RB ,_, to_TO examine_VB the_DT GAG_NNP content_NN
        in_IN CM_NNP and_CC their_PRP$ effects_NNS on_IN PEDF_NNP ligand-receptor_JJ
        interactions_NNS ._. The_DT data_NNS suggest_VBP that_DT heparan_NN sulfate_NN
        participates_VBZ in_IN the_DT formation_NN of_IN a_DT PEDF_NNP binding_JJ complex_NN
        with_IN its_PRP$ cell-surface_JJ receptor_NN ,_, and_CC constitutes_VBZ a_DT positive_JJ
        modulator_NN for_IN the_DT PEDF-receptor_NNP interactions_NNS ._.
      
      
        Results_NNS
        
          Complex_JJ formation_NN between_IN PEDF_NNP and_CC component_NN (_( s_VBZ )_) in_IN
          media_NNS conditioned_VBN by_IN retinoblastoma_NN cells_NNS
          To_TO determine_VB whether_IN PEDF_NNP interacts_NNS with_IN component_NN (_( s_VBZ )_)
          in_IN media_NNS conditioned_VBN by_IN retinoblastoma_NN cells_NNS (_( CM_NNP )_) ,_, we_PRP
          used_VBD an_DT ultrafiltration_NN assay_NN ._. In_IN this_DT assay_NN ,_, soluble_JJ
          PEDF_NNP of_IN 50_CD -_: kDa_NN is_VBZ filtered_VBN through_IN a_DT membrane_NN with_IN an_DT
          exclusion_NN limit_NN of_IN MW_NNP 100_CD ,_, 000_CD ,_, however_RB it_PRP is_VBZ retained_VBN
          upon_IN formation_NN of_IN a_DT complex_JJ larger_JJR than_IN this_DT limit_NN [_NN 14_CD ]_NN
          ._. The_DT binding_JJ reactions_NNS were_VBD with_IN a_DT given_VBN 125_CD I-PEDF_NNP
          concentration_NN and_CC CM_NNP ._. Incubations_NNP were_VBD at_IN 4_CD °_NN C_NNP to_TO minimize_VB
          enzymatic_JJ degradation_NN of_IN proteins_NNS and_CC glycosaminglycans_NNS
          during_IN the_DT reaction_NN ._. We_PRP found_VBD that_IN 22_CD %_NN of_IN 125_CD I-PEDF_NNP was_VBD
          retained_VBN by_IN the_DT membrane_NN in_IN the_DT presence_NN of_IN concentrated_VBN
          CM_NNP ,_, compared_VBN to_TO only_RB 4_CD %_NN retention_NN in_IN the_DT presence_NN of_IN
          defined_VBN medium_NN (_( non-conditioned_JJ medium_NN )_) concentrated_VBN in_IN
          an_DT identical_JJ fashion_NN ._. Specific_JJ retention_NN ,_, termed_VBD PEDF_NNP
          bound_VBN ,_, was_VBD calculated_VBN by_IN subtracting_VBG the_DT retention_NN in_IN
          defined_VBN media_NNS from_IN that_DT in_IN CM_NNP ._. Figure_NN 1_CD shows_VBZ that_IN PEDF_NNP
          was_VBD specifically_RB retained_VBN when_WRB mixed_VBN with_IN soluble_JJ
          conditioned_VBN media_NNS and_CC the_DT value_NN for_IN PEDF_NNP bound_VBN increased_VBN
          proportionally_RB to_TO the_DT concentration_NN factor_NN of_IN the_DT media_NNS
          (_( Fig_NNP ._. 1_LS A_DT )_) ._. Interestingly_RB ,_, protease_NN treatment_NN of_IN the_DT CM_NNP
          did_VBD not_RB abolish_VB the_DT binding_JJ (_( Fig_NNP ._. 1_LS B_NNP )_) ._. These_DT observations_NNS
          revealed_VBD that_IN the_DT retained_VBN forms_NNS in_IN the_DT CM_NNP were_VBD PEDF_NNP
          complexes_NNS ≥_NN 100_CD -_: kDa_NN ,_, and_CC that_IN the_DT majority_NN of_IN these_DT
          complexes_NNS were_VBD formed_VBN with_IN soluble_JJ CM_NNP components_NNS other_JJ
          than_IN proteins_NNS ._.
        
        
          Heparin_NNP and_CC HS_NNP in_IN the_DT conditioned_VBN media_NNS with_IN
          affinity_NN for_IN PEDF_NNP
          GAGs_NNP and_CC polyanions_NNS in_IN the_DT CM_NNP were_VBD fractionated_JJ by_IN
          anion-exchange_JJ column_NN chromatography_NN followed_VBN by_IN
          PEDF-affinity_NNP column_NN chromatography_NN (_( Fig_NNP ._. 2_LS )_) ._. The_DT GAG_NNP
          content_NN was_VBD followed_VBN by_IN staining_VBG with_IN Toluidine_NNP Blue-_NNP O_NNP
          (_( Fig_NNP ._. 2_LS C_NNP ,_, 2_CD D_NNP ,_, 2_CD E_NNP )_) ._. The_DT final_JJ fraction_NN (_( CM_NNP PEDF_NNP )_) contained_VBD
          components_NNS with_IN binding_JJ affinity_NN for_IN PEDF_NNP that_IN stained_JJ
          with_IN Toluidine_NNP Blue-_NNP O_NNP and_CC migrated_JJ as_IN high_JJ molecular_JJ
          weight_NN GAGs_NNP ._.
          To_TO determine_VB the_DT type_NN of_IN sulfated_JJ GAG_NNP in_IN the_DT media_NNS ,_, we_PRP
          designed_VBD a_DT spectrophotometric_JJ assay_NN using_VBG heparinase_NN and_CC
          heparitinase_NN ,_, specific_JJ degrading_JJ enzymes_NNS for_IN heparin_NN and_CC
          HS_NNP ,_, respectively_RB (_( Fig_NNP ._. 3_LS )_) ._. The_DT activities_NNS of_IN both_DT GAG_NNP
          lyases_NNS reached_VBD a_DT plateau_NN by_IN one_CD hour_NN of_IN incubation_NN (_( Figs_NNP ._.
          3_LS A_DT ,_, 3_CD C_NNP )_) and_CC the_DT degradation_NN of_IN GAG_NNP substrates_NNS between_IN 0_CD -_: 30_CD
          μg_NN was_VBD linear_JJ ._. Both_DT CM_NNP and_CC CM_NNP PEDFcontained_NNP substrates_NNS
          for_IN heparinase_NN and_CC heparitinase_NN (_( Figs_NNP ._. 3_LS B_NNP ,_, 3_CD D_NNP )_) ._. The_DT amount_NN
          of_IN GAGs_NNP was_VBD determined_VBN by_IN comparison_NN of_IN the_DT amount_NN of_IN Δ_NN
          4_CD -_: hexuronate_NN produced_VBN with_IN CM_NNP samples_NNS to_TO the_DT standard_JJ
          curves_NNS with_IN commercial_JJ GAGs_NNP ._. The_DT estimated_VBN content_NN of_IN
          GAGs_NNP in_IN CM_NNP varied_VBD between_IN 12_CD ._. 4_LS -_: 22_CD ._. 7_CD μg_NN /_NN ml_NN for_IN heparin_NN and_CC
          between_IN 9_CD -_: 10_CD μg_NN /_NN ml_NN for_IN HS-like_NNP molecules_NNS ,_, among_IN media_NNS
          conditioned_VBN by_IN three_CD different_JJ batches_NNS of_IN Y-_NNP 79_CD cells_NNS ._. The_DT
          estimated_VBN GAG_NNP content_NN in_IN CM_NNP PEDFranged_NNP 0_CD ._. 2_CD -_: 1_CD ._. 8_CD μg_NN /_NN μl_NN and_CC
          0_CD ._. 1_CD -_: 0_CD ._. 4_LS μg_NN /_NN μl_NN for_IN heparin_NN and_CC HS_NNP ,_, respectively_RB ._. Similar_JJ
          assays_NNS were_VBD followed_VBN with_IN chondroitinase_NN ABC_NNP ,_, but_CC its_PRP$
          substrates_NNS ,_, ΔDi_NN 4_CD S_NNP ,_, dermatan_NN and_CC ΔDi_NN 6_CD S_NNP ,_, in_IN CM_NNP were_VBD below_IN
          detection_NN limits_NNS ._. These_DT results_NNS demonstrated_VBN that_IN CM_NNP and_CC
          CM_NNP PEDFcontained_NNP heparin-_NN and_CC HS-like_NNP molecules_NNS ,_,
          demonstrating_VBG that_IN Y-_NNP 79_CD cells_NNS produced_VBD GAGs_NNP with_IN binding_JJ
          affinity_NN for_IN PEDF_NNP ._.
        
        
          Media_NNP conditioned_VBN by_IN retinoblastoma_NN cells_NNS enhances_VBZ
          the_DT 125_CD I-PEDF_NNP binding_JJ to_TO cell-surface_JJ receptors_NNS
          We_PRP have_VBP demonstrated_VBN previously_RB that_IN biologically_RB
          active_JJ 125_CD I-PEDF_NNP binds_NNS specifically_RB ,_, competitively_RB and_CC
          with_IN high_JJ affinity_NN to_TO cell-surface_JJ receptors_NNS of_IN Y-_NNP 79_CD
          cells_NNS [_NN 18_CD ]_NN ._. Because_IN the_DT reaction_NN conditions_NNS were_VBD
          identical_JJ to_TO those_DT used_VBN for_IN biological_JJ assays_NNS ,_, the_DT
          binding_JJ reactions_NNS were_VBD performed_VBN in_IN the_DT presence_NN of_IN media_NNS
          conditioned_VBN by_IN the_DT cells_NNS for_IN 16_CD hours_NNS (_( CM_NNP )_) ._. We_PRP
          investigated_VBD the_DT effect_NN of_IN components_NNS of_IN the_DT CM_NNP ,_, a_DT source_NN
          of_IN extracellular_NN matrix_NN ,_, on_IN the_DT PEDF-receptor_NNP
          interactions_NNS using_VBG CM_NNP and_CC non-conditioned_JJ defined_VBN media_NNS
          in_IN radioligand_NN binding_JJ assays_NNS ._. Comparison_NNP of_IN reactions_NNS in_IN
          the_DT absence_NN and_CC presence_NN of_IN CM_NNP showed_VBD that_IN the_DT specific_JJ
          PEDF-binding_NNP to_TO Y-_NNP 79_CD cell-surface_JJ receptors_NNS was_VBD 6_CD ._. 8_CD -_: fold_VB
          higher_JJR with_IN conditioned_VBN medium_NN than_IN with_IN defined_VBN medium_NN
          (_( Fig_NNP ._. 4_LS )_) ._. Note_VB that_IN with_IN the_DT binding_JJ method_NN used_VBD ,_, the_DT
          amount_NN of_IN 125_CD I-PEDF_NNP retained_VBD in_IN CM_NNP without_IN cells_NNS is_VBZ the_DT
          same_JJ to_TO the_DT amount_NN of_IN non-specific_JJ 125_CD I-PEDF_NNP binding_JJ
          (_( reactions_NNS with_IN cells_NNS and_CC in_IN the_DT presence_NN of_IN 50_CD -_: fold_VB
          molar_NN excess_NN of_IN unlabeled_JJ PEDF_NNP )_) [_NN 18_CD ]_NN ,_, indicating_VBG
          retention_NN by_IN PEI-treated_NNP glass-fiber_JJ filters_NNS of_IN
          PEDF-receptor_NNP or_CC GAG-PEDF-receptor_NNP complexes_NNS rather_RB than_IN
          PEDF-GAG_NNP ._. Similar_JJ results_NNS were_VBD obtained_VBN when_WRB the_DT
          cell-bound_JJ 125_CD I-PEDF_NNP was_VBD separated_VBN by_IN centrifugation_NN ,_,
          rather_RB than_IN filtration_NN through_IN glass-fiber_JJ filters_NNS ,_, and_CC
          comparing_VBG reactions_NNS with_IN CM_NNP versus_CC those_DT with_IN 1_CD %_NN BSA_NNP in_IN
          PBS_NNP (_( data_NNS not_RB shown_VBN )_) ._. These_DT observations_NNS showed_VBD that_IN a_DT
          component_NN (_( s_VBZ )_) secreted_JJ by_IN retinoblastoma_NN cells_NNS enhanced_VBD
          the_DT PEDF-receptor_NNP interactions_NNS ._.
        
        
          Effect_NN of_IN GAG_NNP lyases_NNS and_CC chlorate_NN on_IN 125_CD I-PEDF_NNP
          binding_JJ to_TO cell-surface_JJ receptors_NNS
          To_TO deplete_VB the_DT Y-_NNP 79_CD cell_NN cultures_NNS of_IN HS_NNP and_CC
          heparin-like_JJ GAGs_NNP ,_, we_PRP used_VBD heparitinase_NN and_CC heparinase_NN ,_,
          respectively_RB ._. The_DT cultures_NNS were_VBD pretreated_JJ with_IN each_DT GAG_NNP
          lyase_NN before_IN using_VBG them_PRP in_IN radioligand_NN binding_JJ assays_NNS ._.
          The_DT morphology_NN and_CC viability_NN of_IN the_DT cells_NNS were_VBD not_RB
          affected_VBN with_IN the_DT GAG_NNP lyase_NN treatments_NNS ._. Figure_NN 5_CD Ashows_NNP
          that_IN specific_JJ 125_CD I-PEDF_NNP binding_JJ decreased_VBD significantly_RB
          in_IN heparitinase_NN treated_VBD cultures_NNS compared_VBN to_TO untreated_JJ
          controls_NNS ,_, and_CC less_RBR drastically_RB in_IN heparinase_NN treated_VBD
          ones_NNS ._. Hyaluronidase_NNP treatment_NN to_TO deplete_VB the_DT cultures_NNS of_IN
          hyaluronan_NN did_VBD not_RB have_VB an_DT effect_NN on_IN the_DT binding_JJ ._. These_DT
          results_NNS demonstrated_VBN that_DT removal_NN of_IN heparin_NN /_NN HS_NNP from_IN the_DT
          cell_NN cultures_NNS decreased_VBD the_DT PEDF_NNP binding_JJ to_TO receptors_NNS on_IN
          Y-_NNP 79_CD cells_NNS ._. Chlorate_NNP is_VBZ a_DT competitive_JJ inhibitor_NN of_IN
          ATP-sulfurylase_NNP ,_, and_CC inhibition_NN of_IN GAG_NNP sulfation_NN in_IN cell_NN
          cultures_NNS can_MD be_VB achieved_VBN by_IN pretreatment_NN of_IN the_DT cultures_NNS
          with_IN 30_CD mM_NN sodium_NN chlorate_NN [_NN 21_CD ]_NN ._. The_DT effect_NN of_IN
          undersulfated_JJ GAGs_NNP on_IN the_DT PEDF_NNP binding_JJ to_TO its_PRP$ receptor_NN
          was_VBD examined_VBN ._. Cells_NNP pretreated_JJ with_IN sodium_NN chlorate_NN did_VBD
          not_RB show_VB changes_NNS in_IN viability_NN or_CC morphology_NN ;_: however_RB ,_, the_DT
          treatment_NN resulted_VBD in_IN a_DT decrease_NN in_IN the_DT specific_JJ
          125_CD I-PEDF_NNP binding_JJ to_TO about_IN 35_CD %_NN relative_JJ to_TO untreated_JJ
          controls_NNS (_( Fig_NNP ._. 5_LS B_NNP )_) ._. Sodium_NNP sulfate_NN was_VBD used_VBN to_TO recover_VB
          the_DT loss_NN of_IN GAG_NNP sulfation_NN by_IN chlorate_NN increasing_VBG the_DT
          binding_JJ to_TO 55_CD %_NN maximal_NN with_IN 10_CD mM_NN sulfate_NN additions_NNS ._. The_DT
          data_NNS revealed_VBD that_DT inhibition_NN of_IN sulfation_NN of_IN GAGs_NNP
          reduced_VBD the_DT PEDF_NNP binding_JJ to_TO cell-surface_JJ receptors_NNS of_IN
          Y-_NNP 79_CD cells_NNS ,_, with_IN about_IN 20_CD %_NN of_IN specific_JJ inhibition_NN ._. Thus_RB ,_,
          these_DT observations_NNS implied_VBN that_IN HS_NNP /_NN heparin_NN might_MD play_VB a_DT
          functional_JJ role_NN in_IN the_DT binding_JJ of_IN PEDF_NNP to_TO its_PRP$
          cell-surface_JJ receptor_NN ._.
        
      
      
        Discussion_NNP
        It_PRP has_VBZ been_VBN proposed_VBN that_IN the_DT GAG-binding_NNP property_NN of_IN
        PEDF_NNP provides_VBZ the_DT molecular_JJ basis_NN for_IN its_PRP$ association_NN with_IN
        extracellular_NN matrices_NNS and_CC may_MD serve_VB to_TO localize_NN PEDF_NNP
        activity_NN in_IN the_DT retina_NN and_CC CNS_NNP [_NN 14_CD 19_CD ]_NN ._. However_RB ,_, the_DT
        present_JJ results_NNS point_VBP to_TO direct_JJ effects_NNS these_DT
        polysaccharides_NNS might_MD have_VB on_IN the_DT biochemical_JJ interactions_NNS
        between_IN PEDF_NNP and_CC PEDF_NNP receptors_NNS on_IN the_DT surfaces_VBZ of_IN cells_NNS
        that_WDT respond_VBP to_TO this_DT neurotrophic_JJ factor_NN ._. We_PRP have_VBP shown_VBN
        that_IN the_DT binding_JJ of_IN PEDF_NNP to_TO receptors_NNS in_IN retinoblastoma_NN
        cells_NNS is_VBZ enhanced_VBN by_IN the_DT presence_NN of_IN extracellular_NN
        heparin_NN /_NN HS-like_NNP GAGs_NNP ,_, which_WDT can_MD be_VB found_VBN in_IN the_DT culture_NN
        medium_NN of_IN retinoblastoma_NN cells_NNS ._. The_DT fact_NN that_IN the_DT binding_JJ
        of_IN PEDF_NNP to_TO cell_NN surfaces_VBZ decreases_NNS with_IN heparin_NN /_NN HS_NNP
        depletion_NN ,_, implies_VBZ that_DT heparin_NN /_NN HS_NNP molecules_NNS might_MD act_VB as_IN
        cofactors_NNS for_IN PEDF-receptor_NNP interactions_NNS ._. Interactions_NNP
        between_IN PEDF_NNP and_CC extracellular_NN GAGs_NNP can_MD also_RB explain_VB the_DT
        complex_JJ formed_VBN by_IN PEDF_NNP with_IN CM_NNP even_RB after_IN protease_NN
        treatment_NN of_IN the_DT latter_NN ._. The_DT PEDF-heparin_NNP /_NN HS_NNP complex_JJ may_MD
        somehow_RB facilitate_VB encounters_VBZ between_IN PEDF_NNP and_CC its_PRP$
        receptor_NN ,_, 
        e_SYM ._. g_SYM ._. ,_, by_IN inducing_VBG a_DT conformational_NN
        change_NN in_IN PEDF_NNP ,_, which_WDT might_MD accelerate_VB the_DT ligand-receptor_JJ
        interactions_NNS ._. In_IN addition_NN ,_, the_DT receptor_NN may_MD also_RB form_VB a_DT
        complex_NN with_IN heparin_NN /_NN HS_NNP to_TO facilitate_VB interactions_NNS with_IN the_DT
        ligand_NN ._.
        To_TO our_PRP$ knowledge_NN ,_, this_DT is_VBZ the_DT first_JJ report_NN on_IN the_DT
        production_NN of_IN GAGs_NNP by_IN retinoblastoma_NN cells_NNS ._. We_PRP found_VBD that_IN
        these_DT cells_NNS produce_VBP HS_NNP /_NN heparin_NN secreted_JJ into_IN the_DT culturing_VBG
        media_NNS ._. The_DT retina_NN and_CC malignant_JJ solid_JJ tumors_NNS also_RB produce_VBP
        the_DT sulfated_JJ GAGs_NNP [_NN 1_CD 2_CD 22_CD 23_CD 24_CD 25_CD 26_CD ]_NN ._. Although_IN HSs_NNP are_VBP
        mostly_RB found_VBN as_IN proteoglycans_NNS associated_VBN with_IN the_DT basal_NN
        lamina_NN or_CC the_DT plasma_NN membrane_NN ,_, the_DT presence_NN of_IN HSs_NNP in_IN the_DT
        culturing_VBG medium_NN might_MD be_VB a_DT result_NN of_IN shedding_VBG or_CC release_NN
        of_IN their_PRP$ extracellular_NN domains_NNS from_IN the_DT cell_NN membranes_NNS as_IN
        soluble_JJ components_NNS ._. Cell-associated_NNP HS_NNP proteoglycans_NNS can_MD
        undergo_VB regulated_VBN shedding_VBG from_IN the_DT membrane_NN into_IN the_DT
        soluble_JJ extracellular_NN matrix_NN or_CC culturing_VBG medium_NN converting_VBG
        the_DT membrane_NN anchored_VBN molecules_NNS into_IN soluble_JJ effectors_NNS [_NN 1_CD
        2_CD ]_NN ._. In_IN the_DT conditioned_VBN media_NNS of_IN all_PDT the_DT tested_VBN batches_NNS of_IN
        retinoblastoma_NN cells_NNS ,_, we_PRP detected_VBD heparin_NN and_CC HS_NNP with_IN
        binding_JJ affinity_NN for_IN PEDF_NNP ._. The_DT estimated_VBN concentrations_NNS of_IN
        these_DT GAGs_NNP in_IN the_DT media_NNS may_MD vary_VB with_IN cell_NN density_NN and_CC
        conditioning_NN time_NN ._. However_RB ,_, under_IN the_DT conditions_NNS used_VBN ,_, they_PRP
        were_VBD within_IN the_DT linear_JJ range_NN of_IN HS-PEDF_NNP complex_JJ formation_NN (_(
        
        EC_NNP 
        50_CD =_SYM 40_CD μg_NN /_NN ml_NN )_) [_NN 14_CD ]_NN ._.
        The_DT fact_NN that_DT depletion_NN of_IN heparin_NN /_NN HS-like_NNP GAGs_NNP from_IN the_DT
        culturing_VBG media_NNS results_NNS in_IN inhibition_NN of_IN PEDF_NNP binding_JJ to_TO
        cell_NN surface_NN receptors_NNS points_NNS to_TO functional_JJ roles_NNS for_IN these_DT
        GAGs_NNP such_JJ as_IN those_DT of_IN positive_JJ modulators_NNS of_IN PEDF-receptor_NNP
        interactions_NNS ._. In_IN this_DT regard_NN ,_, we_PRP observed_VBD that_DT depletion_NN
        from_IN the_DT Y-_NNP 79_CD cell_NN cultures_NNS of_IN heparin_NN with_IN heparinase_NN was_VBD
        lower_JJR than_IN those_DT depleted_VBN of_IN HS_NNP with_IN heparitinase_NN ,_,
        suggesting_VBG that_IN the_DT retinoblastoma-derived_JJ HS_NNP was_VBD more_RBR
        effective_JJ than_IN the_DT retinoblastoma-derived_JJ heparin_NN ._. This_DT
        observation_NN can_MD be_VB explained_VBN by_IN structural_JJ ,_, compositional_JJ
        and_CC functional_JJ differences_NNS between_IN heparin_NN and_CC HS_NNP GAGs_NNP ._.
        GAG-binding_NNP proteins_NNS can_MD be_VB differentially_RB sensitive_JJ to_TO
        variations_NNS in_IN GAG_NNP structure_NN [_NN 27_CD ]_NN ._. GAGs_NNP produced_VBD among_IN
        different_JJ cell_NN types_NNS have_VBP structural_JJ and_CC compositional_JJ
        differences_NNS and_CC structural_JJ changes_NNS in_IN GAGs_NNP are_VBP known_VBN to_TO
        occur_VB in_IN cells_NNS undergoing_VBG morphological_JJ differentiation_NN
        and_CC /_NN or_CC malignant_JJ transformations_NNS [_NN 28_CD 29_CD 30_CD 31_CD ]_NN ._. Thus_RB ,_, in_IN
        the_DT native_JJ retina_NN ,_, or_CC other_JJ tissue_NN ,_, modulation_NN of_IN the_DT
        PEDF-receptor_NNP interactions_NNS may_MD depend_VB on_IN the_DT expression_NN of_IN
        GAGs_NNP ,_, which_WDT occur_VBP during_IN development_NN and_CC pathological_JJ
        conditions_NNS ._.
        Our_PRP$ data_NNS offer_VBP interesting_JJ possibilities_NNS of_IN regulation_NN
        of_IN the_DT activity_NN of_IN PEDF_NNP ._. The_DT ratio_NN and_CC amount_NN of_IN production_NN
        of_IN heparin_NN and_CC HS_NNP by_IN cells_NNS bearing_NN PEDF_NNP receptors_NNS may_MD be_VB an_DT
        important_JJ mechanism_NN to_TO control_VB the_DT activity_NN of_IN PEDF_NNP as_IN is_VBZ
        the_DT modulation_NN of_IN the_DT rate_NN of_IN expression_NN of_IN PEDF_NNP receptors_NNS ._.
        The_DT data_NNS obtained_VBN so_RB far_RB on_IN the_DT action_NN of_IN PEDF_NNP on_IN different_JJ
        cells_NNS may_MD have_VB not_RB considered_VBN the_DT presence_NN of_IN these_DT
        cofactors_NNS in_IN the_DT media_NNS ._. The_DT binding_JJ of_IN GAGs_NNP to_TO PEDF_NNP that_WDT
        modulate_VBP the_DT binding_VBG of_IN these_DT factors_NNS to_TO its_PRP$ receptor_NN opens_VBZ
        also_RB the_DT possibility_NN that_IN different_JJ GAGs_NNP may_MD modulate_VBP
        differently_RB the_DT affinity_NN of_IN PEDF_NNP for_IN its_PRP$ receptors_NNS ,_, by_IN
        increasing_VBG or_CC even_RB decreasing_VBG it_PRP in_IN some_DT cases_NNS ._. Finally_RB ,_,
        the_DT fact_NN that_IN the_DT GAG_NNP and_CC receptor_NN binding_JJ regions_NNS are_VBP on_IN
        opposite_JJ regions_NNS of_IN the_DT PEDF_NNP molecule_NN ,_, suggest_VBP the_DT
        possibility_NN of_IN the_DT existence_NN of_IN PEDF_NNP mutants_NNS or_CC engineered_VBN
        variants_NNS that_IN ,_, having_VBG lost_VBN or_CC decreased_VBD GAG-binding_NNP
        capabilities_NNS ,_, still_RB show_NN high_JJ affinity_NN for_IN the_DT PEDF_NNP
        receptor_NN in_IN a_DT way_NN not_RB dependent_JJ upon_IN GAGs_NNP content_NN or_CC
        composition_NN ._. These_DT possibilities_NNS are_VBP discussed_VBN under_IN the_DT
        consideration_NN that_IN some_DT of_IN them_PRP may_MD have_VB important_JJ
        implications_NNS if_IN PEDF_NNP ,_, or_CC molecules_NNS derived_VBN from_IN it_PRP ,_, are_VBP to_TO
        be_VB used_VBN in_IN the_DT future_NN as_IN therapeutic_JJ agents_NNS ._.
        The_DT primary_JJ consequence_NN of_IN reducing_VBG the_DT heparin_NN /_NN HS_NNP and_CC
        its_PRP$ sulfation_NN was_VBD to_TO minimize_VB a_DT binding_JJ site_NN required_VBN for_IN
        PEDF_NNP activity_NN ._. Although_IN GAGs_NNP store_NN PEDF_NNP in_IN the_DT
        extracellular_NN matrix_NN [_NN 14_CD ]_NN ,_, a_DT more_RBR direct_JJ mechanism_NN
        appears_VBZ necessary_JJ ,_, namely_RB ,_, its_PRP$ participation_NN in_IN the_DT binding_JJ
        of_IN PEDF_NNP to_TO its_PRP$ receptor_NN ._. In_IN a_DT spatial_NN structure_NN of_IN PEDF_NNP ,_,
        the_DT heparin_NN /_NN HS_NNP binding_JJ domain_NN of_IN PEDF_NNP maps_NNS to_TO the_DT opposite_JJ
        side_NN of_IN the_DT neurotrophic_JJ active_JJ region_NN [_NN 20_CD ]_NN ,_, allowing_VBG
        distinct_JJ and_CC non-overlapping_JJ interactions_NNS with_IN heparin_NN /_NN HS_NNP
        on_IN one_CD side_NN of_IN the_DT protein_NN ,_, and_CC with_IN the_DT neurotrophic_JJ
        receptor_NN on_IN its_PRP$ opposite_JJ side_NN ._. Our_PRP$ data_NNS suggest_VBP that_IN the_DT
        intrinsic_JJ affinity_NN of_IN the_DT cell_NN surface_NN receptor_NN for_IN PEDF_NNP
        appears_VBZ low_JJ ,_, whereas_IN the_DT heparin_NN /_NN HS-PEDF_NNP complex_NN is_VBZ
        recognized_VBN with_IN high_JJ affinity_NN ._. In_IN addition_NN ,_, a_DT direct_JJ
        interaction_NN between_IN the_DT receptor_NN and_CC GAGs_NNP may_MD also_RB be_VB
        necessary_JJ ._. Although_IN details_NNS of_IN the_DT mechanism_NN remain_VB to_TO be_VB
        revealed_VBN ,_, it_PRP is_VBZ clear_JJ that_DT heparin_NN /_NN HS_NNP is_VBZ required_VBN for_IN the_DT
        first_JJ step_NN of_IN the_DT neurotrophic_JJ activity_NN of_IN PEDF_NNP ,_, namely_RB the_DT
        encounters_NNS with_IN its_PRP$ receptor_NN at_IN the_DT cell_NN surface_NN ._. The_DT
        differentiation_NN and_CC survival_NN of_IN cells_NNS in_IN vivo_NN may_MD be_VB
        regulated_VBN not_RB only_RB by_IN the_DT expression_NN of_IN PEDF_NNP and_CC its_PRP$
        receptor_NN but_CC also_RB by_IN the_DT temporal_JJ and_CC spatial_NN expression_NN of_IN
        GAGs_NNP ._.
      
      
        Methods_NNP
        
          Materials_NNS
          Heparin_NNP purified_JJ from_IN bovine_JJ intestinal_NN mucosa_NN ,_,
          chondroitin_NN sulfates_NNS A_DT ,_, B_NNP and_CC C_NNP ,_, chondroitinase_NN ABC_NNP ,_,
          sodium_NN chlorate_NN ,_, and_CC Toluidine_NNP Blue-_NNP O_NNP were_VBD purchased_VBN from_IN
          Sigma_NNP ._. Subtilisin_NNP was_VBD from_IN Boehringer_NNP Mannheim_NNP ._.
          Heparitinase_NNP (_( E_NNP ._. C_NNP ._. 4_LS ._. 2_CD ._. 2_LS ._. 8_CD )_) and_CC heparinase_NN (_( E_NNP ._. C_NNP ._. 4_LS ._. 2_CD ._. 2_LS ._. 7_CD )_)
          purified_JJ from_IN 
          Flavobacterium_NNP heparinum_NN were_VBD from_IN
          ICN_NNP Biomedicals_NNP ,_, Inc_NNP ._. and_CC alternatively_RB from_IN Seikagaku_NNP ._.
          Heparan_NNP sulfate_NN (_( HS_NNP )_) purified_JJ from_IN bovine_JJ kidney_NN was_VBD from_IN
          Seikagaku_NNP ,_, hyaluronidase_NN (_( E_NNP ._. C_NNP ._. 4_LS ._. 2_CD ._. 2_LS ._. 1_LS )_) purified_JJ from_IN 
          Streptomyces_NNP hyalurolyticus_JJ from_IN
          ICN_NNP Pharmaceuticals_NNP ,_, Coomassie_NNP Brilliant_NNP Blue_NNP from_IN
          BioRad_NNP ,_, and_CC Q-S_NNP epharose_NN from_IN Pharmacia_NNP ._. Recombinant_NNP PEDF_NNP
          was_VBD purified_JJ from_IN BHK_NNP cells_NNS containing_VBG an_DT expression_NN
          vector_NN with_IN human_JJ PEDF_NNP cDNA_NN ,_, as_RB previously_RB described_VBD [_NN 19_CD
          ]_NN ._.
        
        
          Preparation_NNP of_IN conditioned_VBN media_NNS
          Human_JJ retinoblastoma_NN Y-_NNP 79_CD cells_NNS (_( 0_CD ._. 45_CD -_: 5_CD ×_NN 10_CD
          6_CD cells_NNS /_NN ml_NN )_) were_VBD cultured_JJ in_IN defined_VBN media_NNS (_( MEM_NNP containing_VBG
          10_CD mM_NN HEPES_NNP ,_, 1_CD mM_NN Na-pyruvate_NNP ,_, 0_CD ._. 1_CD mM_NN non-essential_JJ amino_JJ
          acids_NNS ,_, 1_CD mM_NN L-_NNP glutamine_NN ,_, 1_CD %_NN penicillin_NN /_NN streptomycin_NN
          (_( LifeTechnologies_NNP )_) )_) at_IN 37_CD °_NN C_NNP for_IN 16_CD -_: 24_CD h_NN ._. Media_NNP exposed_VBD to_TO
          these_DT conditions_NNS is_VBZ referred_VBN as_IN CM_NNP ._. CM_NNP was_VBD separated_JJ from_IN
          cells_NNS by_IN centrifugation_NN (_( 1000_CD ×_NN 
          g_SYM for_IN 5_CD min_NN at_IN 4_CD °_NN C_NNP )_) and_CC
          concentrated_VBN by_IN ultrafiltration_NN using_VBG membrane_NN filters_NNS
          with_IN MWCO_NNP =_SYM 10_CD ,_, 000_CD (_( Amicon_NNP YM_NNP 10_CD filters_NNS )_) ._. GAGs_NNP /_NN polyanions_NNS
          purification_NN was_VBD performed_VBN as_IN follows_VBZ :_: concentrated_VBN CM_NNP
          (_( 15_CD ml_NN )_) was_VBD dialyzed_JJ against_IN buffer_NN Q_NNP (_( 50_CD mM_NN Tris-_NNP HCl_NNP ,_, pH_NN
          8_CD ._. 0_CD ,_, 0_CD ._. 2_CD M_NNP NaCl_NNP ,_, 6_CD M_NNP Urea_NNP ,_, 0_CD ._. 5_CD %_NN CHAPS_NNP )_) ,_, filtered_VBN through_IN
          a_DT 0_CD ._. 4_CD micron_NN membrane_NN and_CC its_PRP$ soluble_JJ components_NNS
          subjected_VBN to_TO anion-exchange_JJ column_NN chromatography_NN using_VBG
          Q-S_NNP epharose_NN Fast_NNP Flow_NNP (_( 1_CD ml_NN bed_NN volume_NN )_) ._. The_DT column_NN was_VBD
          washed_VBN with_IN 15_CD -_: column_NN volumes_NNS of_IN buffer_NN Q_NNP ,_, the_DT bound_VBN
          material_NN eluted_JJ with_IN 1_CD ._. 2_CD M_NNP NaCl_NNP and_CC termed_VBD CM_NNP a_DT ._.
          Alternatively_RB ,_, a_DT DEAE-Sephacel_NNP column_NN was_VBD used_VBN ._.
        
        
          PEDF-affinity_NNP column_NN chromatography_NN
          To_TO identify_VB components_NNS with_IN PEDF-binding_NNP affinity_NN ,_,
          purified_JJ recombinant_JJ protein_NN was_VBD used_VBN to_TO prepare_VB
          PEDF-affinity_NNP resin_NN with_IN 3_CD M_NNP Emphaze_NNP ™_NN Biosupport_NNP Medium_NNP
          (_( Pierce_NNP Chemical_NNP )_) [_NN 18_CD ]_NN ._. CM_NNP awas_NNS dialyzed_JJ against_IN
          buffer_NN P_NN (_( 20_CD mM_NN sodium_NN phosphate_NN pH_NN 7_CD ,_, 150_CD mM_NN NaCl_NNP ,_, 0_CD ._. 5_CD %_NN
          CHAPS_NNP )_) and_CC filtrated_JJ through_IN 0_CD ._. 4_CD μm_NN filters_NNS ._. The_DT soluble_JJ
          dialysate_NN was_VBD mixed_VBN with_IN PEDF-resin_NNP (_( 6_CD mg_NN PEDF_NNP /_NN ml_NN resin_NN )_)
          at_IN a_DT 2_CD :_: 1_CD volume-to-volume_JJ ratio_NN and_CC incubated_JJ at_IN 4_CD °_NN C_NNP with_IN
          gentle_JJ rocking_VBG for_IN 16_CD h_NN ._. The_DT mixture_NN was_VBD packed_VBN into_IN a_DT 10_CD
          ml_NN Polyprep_NNP chromatography_NN column_NN (_( Bio-_NNP Rad_NNP )_) and_CC washed_VBN
          with_IN 10_CD -_: column_NN volumes_NNS of_IN buffer_NN P_NN ._. The_DT bound_VBN material_NN
          was_VBD eluted_JJ with_IN 10_CD -_: column_NN volumes_NNS of_IN 3_CD M_NNP NaCl_NNP ,_, desalted_JJ
          with_IN 20_CD mM_NN Tris-_NNP HCl_NNP pH_NN 8_CD ._. 0_CD ,_, 10_CD %_NN glycerol_NN ,_, treated_VBN for_IN
          protein_NN depletion_NN ,_, dialyzed_JJ against_IN deionized_JJ water_NN ,_,
          lyophilized_JJ and_CC resuspended_JJ in_IN deionized_JJ water_NN ._. The_DT final_JJ
          sample_NN was_VBD termed_VBN CM_NNP PEDF_NNP ._. About_IN 100_CD μl_NN of_IN CM_NNP PEDFwere_NNP
          obtained_VBD from_IN 100_CD ml_NN of_IN CM_NNP ._. Alternatively_RB ,_, concentrated_VBD
          CM_NNP was_VBD used_VBN as_IN starting_VBG material_NN and_CC protein_NN depletion_NN
          was_VBD omitted_VBN ._.
        
        
          Radioligand_NNP binding_JJ assays_NNS
          PEDF_NNP binding_JJ to_TO cell-surface_JJ receptors_NNS was_VBD assayed_JJ
          using_VBG biologically_RB active_JJ radioligand_NN 125_CD I-PEDF_NNP and_CC Y-_NNP 79_CD
          cells_NNS [_NN 18_CD ]_NN by_IN a_DT widely-used_JJ method_NN with_IN a_DT mechanism_NN of_IN
          retention_NN of_IN receptors_NNS on_IN polyethylenimine-treated_JJ
          glass-fiber_JJ filters_NNS based_VBN mainly_RB on_IN ionic_JJ interactions_NNS [_NN
          32_CD ]_NN ._. Polyethylenimine_NNP binds_NNS strongly_RB to_TO glass_NN ,_, which_WDT is_VBZ
          negatively_RB charged_VBN and_CC integral_JJ membrane_NN proteins_NNS tend_VBP to_TO
          be_VB acidic_JJ ._. The_DT resultant_JJ polycationic_JJ
          polyethylenimine-coated_JJ glass_NN can_MD retain_VB cell_NN membranes_NNS
          due_JJ to_TO their_PRP$ negative_JJ charges_NNS ._. Because_IN binding_JJ of_IN
          cell-surface_JJ receptors_NNS to_TO polyethylenimine_NN filters_NNS is_VBZ
          rather_RB insensitive_JJ to_TO ionic_JJ strength_NN ,_, the_DT ionic_JJ
          phenomenon_NN is_VBZ thought_VBN to_TO be_VB supplemented_JJ by_IN hydrophobic_JJ
          forces_NNS and_CC hydrogen_NN binding_JJ [_NN 32_CD ]_NN ._. The_DT method_NN used_VBN with_IN
          Y-_NNP 79_CD cells_NNS and_CC radiolabeled_JJ PEDF_NNP has_VBZ been_VBN described_VBN
          before_IN in_IN detail_NN [_NN 18_CD ]_NN ._. Briefly_NNP ,_, cells_NNS cultured_JJ
          overnight_JJ in_IN serum-deprived_JJ medium_NN at_IN 37_CD °_NN C_NNP were_VBD
          transferred_VBN to_TO ice_NN /_NN water_NN bath_NN for_IN 10_CD minutes_NNS before_IN the_DT
          addition_NN of_IN ligand_NN ._. The_DT reaction_NN mixtures_NNS containing_VBG cell_NN
          suspensions_NNS with_IN given_VBN radioligand_NN concentrations_NNS in_IN
          untreated_JJ or_CC treated_VBN media_NNS were_VBD incubated_JJ at_IN 4_CD °_NN C_NNP for_IN 90_CD
          min_NN ,_, unless_IN indicated_VBD ._. The_DT free_JJ and_CC bound_VBN 125_CD I-PEDF_NNP were_VBD
          separated_VBN by_IN filtration_NN through_IN glass-fiber_JJ filters_NNS and_CC
          the_DT bound_VBN radioactivity_NN was_VBD determined_VBN in_IN the_DT filters_NNS
          using_VBG a_DT β-scintillation_JJ counter_NN (_( Beckman_NNP ,_, model_NN LS_NNP 3801_CD )_) ._.
          Nonspecific_NNP binding_JJ was_VBD calculated_VBN from_IN reactions_NNS with_IN a_DT
          molar-excess_JJ of_IN unlabeled_JJ ligand_NN (_( ≥_NN 50_CD -_: fold_VB )_) over_IN
          radioligand_NN ._.
        
        
          Complex-formation_NNP assays_NNS
          Complex_JJ formation_NN between_IN PEDF_NNP and_CC CM_NNP components_NNS was_VBD
          assayed_JJ by_IN a_DT method_NN using_VBG ultrafiltration_NN through_IN
          membranes_NNS of_IN 100_CD ,_, 000_CD MW_NNP exclusion_NN limit_NN [_NN 14_CD ]_NN ._. Binding_NNP
          reactions_NNS were_VBD performed_VBN with_IN a_DT given_VBN concentration_NN of_IN
          125_CD I-PEDF_NNP in_IN defined_VBN or_CC conditioned_VBN media_NNS ,_, and_CC
          incubations_NNS with_IN gentle_JJ rotation_NN at_IN 4_CD °_NN C_NNP for_IN 2_CD h_NN ._. Free_NNP and_CC
          bound_VBN ligand_NN were_VBD separated_VBN by_IN ultrafiltration_NN through_IN
          Microcon-_NNP 100_CD (_( Amicon_NNP )_) ._. The_DT reaction_NN mixtures_NNS were_VBD diluted_VBN
          40_CD -_: fold_VB with_IN cold_JJ 20_CD mM_NN sodium_NN phosphate_NN pH_NN 6_CD ._. 5_CD ,_, 20_CD mM_NN
          NaCl_NNP ,_, 10_CD %_NN glycerol_NN and_CC immediately_RB ultrafiltrated_JJ ,_,
          repeating_VBG twice_RB to_TO ensure_VB removal_NN of_IN free_JJ ligand_NN from_IN the_DT
          complexes_NNS ._. Each_DT Microcon_NNP retenate_NN cup_NN was_VBD transferred_VBN to_TO
          scintillation_NN vials_NNS ,_, mixed_VBN with_IN 5_CD ml_NN BioSafe_NNP II_NNP liquid_JJ
          scintillation_NN solution_NN (_( Research_NNP Products_NNPS International_NNP )_)
          by_IN extensive_JJ vortexing_VBG ,_, and_CC its_PRP$ radioactivity_NN determined_VBD
          using_VBG a_DT β-scintillation_JJ counter_NN ._. Nonspecific_NNP binding_JJ ,_,
          calculated_VBN from_IN reactions_NNS with_IN an_DT excess_NN of_IN unlabeled_JJ
          ligand_NN (_( 100_CD -_: fold_VB )_) over_IN radioligand_NN ,_, reached_VBN about_IN 40_CD %_NN of_IN
          the_DT total_JJ binding_JJ ._.
        
        
          Enzymatic_NNP digestion_NN treatments_NNS
          The_DT presence_NN of_IN GAGs_NNP was_VBD assayed_JJ using_VBG specific_JJ GAG_NNP
          lyases_NNS ,_, 
          i_NNP ._. e_SYM ._. ,_, the_DT presence_NN of_IN heparin_NN ,_, HS_NNP ,_,
          and_CC chondroitin_NN sulfates_NNS with_IN heparinase_NN ,_, heparitinase_NN ,_,
          and_CC chondroitin_NN ABC_NNP respectively_RB ._. The_DT amount_NN of_IN GAGs_NNP was_VBD
          determined_VBN by_IN the_DT amount_NN of_IN Δ_NN 4_CD -_: hexuronate_NN produced_VBN after_IN
          the_DT eliminative_JJ cleavage_NN of_IN each_DT substrate_NN by_IN the_DT
          corresponding_JJ GAG_NNP lyase_NN ._. Samples_NNP were_VBD depleted_VBN of_IN
          proteins_NNS by_IN protease_NN treatment_NN to_TO avoid_VB interference_NN in_IN
          absorbance_NN readings_NNS of_IN the_DT product_NN ._. For_IN heparinase_NN and_CC
          heparitinase_NN reactions_NNS ,_, samples_NNS were_VBD treated_VBN with_IN 5_CD
          milliunits_NNS of_IN each_DT enzyme_NN in_IN 150_CD μl_NN of_IN 0_CD ._. 1_CD M_NNP sodium_NN
          acetate_NN and_CC 1_CD mM_NN CaCl_NNP 
          2_CD ,_, pH_NN 7_CD and_CC incubations_NNS at_IN 37_CD °_NN C_NNP for_IN
          various_JJ time_NN periods_NNS ._. The_DT reactions_NNS were_VBD stopped_VBN by_IN the_DT
          addition_NN of_IN 1_CD ml_NN of_IN 0_CD ._. 06_CD M_NNP HCl_NNP ._. The_DT soluble_JJ material_NN was_VBD
          separated_VBN by_IN centrifugation_NN (_( 3000_CD ×_NN 
          g_SYM ,_, 10_CD min_NN )_) and_CC assayed_JJ for_IN
          absorbance_NN at_IN 235_CD nm_NN to_TO measure_VB the_DT concentration_NN of_IN
          product_NN Δ_NN 4_CD -_: hexuronate_NN (_( Molar_NNP extinction_NN coefficient_NN =_SYM
          5500_CD ;_: [_NN 33_CD ]_NN )_) ._. For_IN the_DT chondroitinase_NN ABC_NNP reactions_NNS ,_,
          each_DT chondroitin_NN sulfates_NNS A_DT ,_, B_NNP and_CC C_NNP substrate_NN (_( 1_CD mg_NN
          each_DT )_) and_CC concentrated_VBN CM_NNP ,_, were_VBD incubated_JJ with_IN 0_CD ._. 12_CD units_NNS
          of_IN chondroitinase_NN ABC_NNP in_IN 1_CD ml_NN of_IN 50_CD mM_NN Tris-_NNP HCl_NNP pH_NN 8_CD ._. 0_CD ,_,
          60_CD mM_NN sodium_NN acetate_NN ,_, and_CC 0_CD ._. 02_CD %_NN BSA_NNP at_IN 37_CD °_NN C_NNP ._. At_IN various_JJ
          time_NN periods_NNS ,_, aliquots_NNS of_IN 0_CD ._. 1_CD ml_NN were_VBD removed_VBN and_CC mixed_VBN
          with_IN 0_CD ._. 9_CD ml_NN of_IN 45_CD mM_NN KCl_NNP pH_NN 1_CD ._. 8_CD to_TO stop_VB the_DT reaction_NN ._.
          Insoluble_NNP material_NN was_VBD removed_VBN by_IN centrifugation_NN (_( 1000_CD ×_NN 
          g_SYM ,_, 10_CD min_NN )_) and_CC the_DT supernatant_NN
          assayed_JJ for_IN absorbance_NN of_IN Δ_NN 4_CD -_: hexuronate_NN at_IN 232_CD nm_NN ._. For_IN
          protein_NN depletion_NN ,_, CM_NNP was_VBD mixed_VBN with_IN subtilisin_NN at_IN 0_CD ._. 4_CD
          μg_NN /_NN ml_NN in_IN 20_CD mM_NN Tris-_NNP HCl_NNP pH_NN 8_CD ._. 0_CD ,_, 10_CD %_NN glycerol_NN and_CC
          incubated_JJ at_IN 37_CD °_NN C_NNP for_IN 16_CD h_NN ._. Subtilisin_NNP was_VBD
          heat-inactivated_JJ at_IN 75_CD °_NN C_NNP for_IN 25_CD min_NN ._. The_DT protein_NN
          concentration_NN after_IN the_DT reaction_NN was_VBD less_JJR than_IN 0_CD ._. 1_CD %_NN of_IN
          the_DT starting_VBG material_NN ._.
          To_TO deplete_VB cell_NN cultures_NNS of_IN GAGs_NNP ,_, Y-_NNP 79_CD cells_NNS in_IN
          defined_VBN serum-free_JJ medium_NN (_( as_IN above_IN )_) at_IN a_DT density_NN of_IN 1_CD ._. 25_CD
          ×_NN 10_CD 5_CD cells_NNS /_NN ml_NN were_VBD cultured_JJ in_IN 96_CD -_: well_RB culture_NN plates_NNS
          (_( 150_CD μl_NN /_NN well_RB )_) and_CC incubated_JJ at_IN 37_CD °_NN C_NNP in_IN a_DT 5_CD %_NN CO_NNP 
          2_CD environment_NN for_IN 16_CD h_NN ._. Hyaluronidase_NNP
          (_( >_NN 1_CD TRU_NNP /_NN μl_NN )_) ,_, heparinase_NN (_( 1_CD mu_NN /_NN μl_NN )_) or_CC heparitinase_NN (_( 1_CD
          mu_NN /_NN μl_NN )_) were_VBD each_DT added_VBD to_TO various_JJ wells_NNS and_CC incubated_JJ at_IN
          37_CD °_NN C_NNP in_IN a_DT 5_CD %_NN CO_NNP 
          2_CD environment_NN for_IN 1_CD h_NN ._.
        
        
          Chlorate_NNP treatment_NN of_IN cell_NN cultures_NNS
          To_TO prevent_VB sulfation_NN of_IN GAGs_NNP in_IN cell_NN cultures_NNS ,_, we_PRP used_VBD
          a_DT method_NN previously_RB described_VBD [_NN 33_CD ]_NN ._. Y-_NNP 79_CD cells_NNS (_( 1_CD ._. 25_CD ×_NN
          10_CD 5_CD cells_NNS /_NN ml_NN )_) were_VBD cultured_JJ in_IN 48_CD -_: well_RB plates_NNS (_( 300_CD
          μl_NN /_NN well_RB )_) in_IN defined_VBN serum-free_JJ medium_NN with_IN or_CC without_IN 30_CD
          mM_NN sodium_NN chlorate_NN and_CC 10_CD mM_NN sodium_NN sulfate_NN at_IN 37_CD °_NN C_NNP in_IN a_DT
          5_CD %_NN CO_NNP 
          2_CD environment_NN for_IN 24_CD h_NN ._.
        
        
          GAG_NNP detection_NN assays_NNS
          GAGs_NNP and_CC proteins_NNS resolved_VBN by_IN SDS-polyacrylamide_NNP gel_NN
          electrophoresis_NNS in_IN Tricine_NNP /_NN SDS_NNP buffer_NN ,_, as_IN instructed_VBN by_IN
          manufacturer_NN (_( Novex_NNP )_) ,_, were_VBD detected_VBN with_IN specific_JJ stains_NNS ._.
          For_IN GAG_NNP detection_NN ,_, the_DT gels_NNS were_VBD incubated_JJ sequentially_RB
          in_IN 0_CD ._. 2_CD %_NN Toluidine_NNP Blue-_NNP O_NNP in_IN ethanol-water-acetic_JJ acid_NN
          (_( 50_CD :_: 49_CD :_: 1_LS )_) for_IN 30_CD minutes_NNS ,_, in_IN ethanol-water-acetic_JJ acid_NN
          (_( 50_CD :_: 49_CD :_: 1_LS )_) for_IN 1_CD h_NN ,_, and_CC in_IN H_NNP 
          2_CD O_NNP for_IN 16_CD h_NN ._. [_NN 34_CD ]_NN ._. For_IN protein_NN
          detection_NN ,_, the_DT gels_NNS were_VBD sequentially_RB incubated_JJ in_IN 0_CD ._. 5_CD %_NN
          Coomassie_NNP Brilliant_NNP Blue_NNP in_IN 50_CD %_NN methanol_NN /_NN 10_CD %_NN acetic_JJ acid_NN
          and_CC in_IN 10_CD %_NN methanol_NN /_NN 10_CD %_NN isopropanol_NN ._. GAG_NNP detection_NN was_VBD
          also_RB performed_VBN by_IN the_DT Toluidine_NNP Blue-_NNP O_NNP precipitation_NN and_CC
          dot-blot_JJ method_NN as_IN described_VBN previously_RB [_NN 34_CD ]_NN ._. Briefly_NNP ,_,
          200_CD μl_NN of_IN sample_NN were_VBD applied_VBN to_TO each_DT well_RB of_IN a_DT 48_CD -_: well_RB
          manifold_NN (_( Life_NNP Technologies_NNPS )_) onto_IN a_DT PVDF_NNP membrane_NN without_IN
          vacuum_NN ._. Then_RB ,_, 5_CD μl_NN of_IN 0_CD ._. 2_CD %_NN Toluidine_NNP blue-_NN O_NNP were_VBD added_VBN to_TO
          each_DT well_RB and_CC vacuum_NN was_VBD applied_VBN ._. The_DT membrane_NN was_VBD
          removed_VBN ,_, washed_VBD twice_RB with_IN destaining_VBG solution_NN
          (_( ethanol-water-acetic_JJ acid_NN ,_, 50_CD :_: 49_CD :_: 1_LS )_) for_IN 5_CD min_NN and_CC
          air-dried_JJ ._.
        
        
          Other_JJ methods_NNS
          The_DT protein_NN concentration_NN was_VBD determined_VBN using_VBG BioRad_NNP
          Protein_NNP Assay_NNP (_( BioRad_NNP )_) ._.
        
      
      
        Abbreviations_NNP
        PEDF_NNP ,_, pigment_NN epithelium-derived_JJ factor_NN ;_: GAG_NNP ,_,
        glycosaminoglycan_NN ;_: HS_NNP ,_, heparan_NN sulfate_NN ;_: CM_NNP ,_, media_NNS
        conditioned_VBN by_IN retinoblastoma_NN cells_NNS ._.
      
      
        Authors_NNP '_'' contributions_NNS
        EMA_NNP participated_VBD in_IN the_DT design_NN ,_, assay_NN development_NN and_CC
        carried_VBD out_RP the_DT complex-formation_JJ ,_, GAG_NNP detection_NN and_CC
        receptor_NN binding_JJ assays_NNS ._. JEW_NNP carried_VBD out_RP the_DT purification_NN
        and_CC characterization_NN of_IN GAGs_NNP ,_, the_DT enzymatic_JJ and_CC chemical_NN
        treatments_NNS of_IN cell_NN cultures_NNS for_IN receptor_NN binding_JJ studies_NNS ,_,
        and_CC drafted_VBD the_DT manuscript_NN ._. SPB_NNP conceived_VBD the_DT study_NN ,_, and_CC
        participated_VBD in_IN its_PRP$ design_NN and_CC coordination_NN ._. All_DT authors_NNS
        read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
